GVB Biopharma, a producer of cannabinoids, announced the launch of its new isolation facility, marking a significant leap in production capabilities and efficiency for the company. The new facility, developed over nearly two years of planning and engineering, enables GVB Biopharma to meet the evolving demands of the global hemp and cannabinoid markets by delivering isolates on a larger scale.
"Our new isolation facility represents a major milestone for GVB Biopharma," said Drew Spiegel, CEO of GVB Biopharma. "We have designed this operation to ensure ultra-high throughput capacity while maintaining strict nutraceutical cGMP compliance. As a result, we're positioned to significantly increase production output and meet the rigorous standards required by our ever-expanding, sophisticated customer base."
"From day one, our focus has been on setting a new industry standard in both scale and precision," added Phil Swindells, COO of GVB Biopharma. "This cutting-edge facility underscores our commitment to delivering top-quality, high-volume cannabinoid isolates. We're excited to meet the evolving needs of our clients with this unprecedented level of production and consistency."
The new facility has the capacity to produce more than 300,000 kilograms of isolates per year, representing what the company believes to be the largest cannabis-specific operation of its kind globally. This elevated capacity positions GVB Biopharma to achieve up to $100 million in annual recurring revenue (ARR) while maintaining the highest level of product integrity and consistency. With significantly larger batch sizes and proprietary separation and refinement processes, the facility delivers higher-efficiency yields than ever before.
